QIAGEN (QGEN)
(Delayed Data from NYSE)
$45.42 USD
-0.09 (-0.20%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $45.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.42 USD
-0.09 (-0.20%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $45.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Diagnostic Testing Remains Crucial in Combatting Coronavirus
by Trina Mukherjee
Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.
Illumina's (ILMN) NGS Test for Detecting Coronavirus Gets EUA
by Zacks Equity Research
Illumina's (ILMN) NGS-based test for the detection of the SARS-CoV-2 receives the FDA's EUA to enable high-volume screening.
Myriad Genetics' Test Better Predicts Drug Levels Per Study
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.
Medtronic's StealthStation Feature Recall Classified Class I
by Zacks Equity Research
This is not the first time, Medtronic's (MDT) StealthStation surgical navigation system is facing product recall.
Globus Medical Faces Business Loss Amid Coronavirus Crisis
by Zacks Equity Research
Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.
Edwards Lifesciences' SAPIEN 3 THV Cleared for Use in China
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 THV to be used an alternative to open-heart surgery for high and extreme-risk AS patients post approval in China.
Medtronic Resolute Onyx Gets CE Mark for 1-Month DAPT Therapy
by Zacks Equity Research
Medtronic's (MDT) gets CE Mark recognition for a shorter DAPT indication for HBR patients with Resolute Onyx DES implantation who are at higher risk of bleeding.
IDEXX OPTI Medical Gets CE Mark for RT-PCR Coronavirus Test
by Zacks Equity Research
This test by IDEXX (IDXX) benefits from an optimized workflow and claims to deliver greater assurance of quality and accuracy.
Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns
by Zacks Equity Research
The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues results from robust demand for coronavirus testing and related research.
Here's Why You Should Hold on to Haemonetics Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.
Qiagen (QGEN) Up 4.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Inks Deal With GVS for Blood Filter Supply
by Zacks Equity Research
Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.
Abbott Stock Down on Urgent Field Safety Notice for TactiCath
by Zacks Equity Research
Abbott (ABT) also mentions certain guidelines related to product return, reporting, and customer assistance.
LabCorp's New Website Offers Patients Coronavirus Trial Details
by Zacks Equity Research
LabCorp's (LH) Covance business benefits from collaborations with leading pharmaceutical and biotechnology companies.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on robust segmental and geographical growth.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust segmental growth and regulatory approvals.
Earnings Estimates Moving Higher for QIAGEN (QGEN): Time to Buy?
by Zacks Equity Research
QIAGEN (QGEN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Bruker Rides on PCI Sales, Coronavirus-Led Supply Issues Hurt
by Zacks Equity Research
Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.
Boston Scientific (BSX) Launches Monitoring Tool Post FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.
QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff
by Zacks Equity Research
QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
How QIAGEN (QGEN) Stock Stands Out in a Strong Industry?
by Zacks Equity Research
QIAGEN (QGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
QGEN vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
QGEN vs. RGEN: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.